Navigation Links
More Evidence Cancer Drug Avastin May Cause Harm

By Amanda Gardner
HealthDay Reporter

TUESDAY, Feb. 1 (HealthDay News) -- A new review finds more evidence that the beleaguered cancer drug Avastin may harm patients.

An analysis of previously published studies found that the drug, when used in combination with chemotherapy or biological therapy, actually increased patient deaths from adverse events, compared with using chemotherapy or biologics alone.

This new information should change the way patients and practitioners think about the drug, said Dr. Shenhong Wu, senior author of the report, published Feb. 2 in the Journal of the American Medical Association.

"I believe the risk-benefit ratio has changed," said Wu, assistant professor of medicine at Stony Brook University Medical Center in Stony Brook, N.Y. "Physicians need to think about this."

Avastin (bevacizumab) was okayed in 2008 for use in conjunction with chemotherapy to treat breast cancer under the U.S. Food and Drug Administration's accelerated approval program. Approval was based on one clinical trial in patients with metastatic HER2-negative breast cancer that found a benefit in terms of cancer recurrence -- but not overall survival -- and was contingent on further data to confirm the results.

Three subsequent studies failed to find an overall survival benefit and, in fact, showed less impressive improvements in survival involving no progression of cancer.

After reviewing all four studies, the FDA in December recommended revoking approval of Avastin to fight breast cancer. The recommendation didn't affect use of Avastin for advanced colon, lung, kidney and brain cancer.

Wu and his colleagues looked at 16 completed randomized controlled trials on Avastin involving more than 10,000 patients with different forms of cancer.

Some 2.5 percent of patients taking Genentech-made Avastin died compared with 1.7 percent of those taking chemotherapy alone, a 46 percent increased risk, the investigators found.

The rate was about the same across tumor types but not across different chemotherapy regimens. The risk was increased among those receiving chemotherapy containing taxanes or platinum agents but not other chemo compounds.

The most common causes of death were hemorrhage, followed by low white-blood-cell count and gastrointestinal perforations.

Dr. Roman Perez-Soler, chairman of oncology and chief of medical oncology at Montefiore Medical Center in New York City, a lung cancer expert, pointed out that lung cancer is one of the few malignancies in which Avastin has prolonged survival and thus might still have a place in this armamentarium.

But an accompanying journal editorial raises other considerations, including the cost ($50,000 a year for the drug alone, plus the cost of monitoring and chemo) and a cumbersome delivery method (frequent injections for years).

The author of that editorial acknowledged that Avastin works well in some patients, but said it's impossible to predict in which patients and for how long benefits will last.

More information

The U.S. National Library of Medicine has more on Avastin.

SOURCES: Shenhong Wu, M.D., Ph.D., assistant professor, medicine, Stony Brook University Medical Center, Stony Brook, N.Y.; Roman Perez-Soler, M.D., chairman, oncology, and chief, medical oncology, Montefiore Medical Center, New York City; Feb. 2, 2011, Journal of the American Medical Association

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
2. Evidence-based care and outcomes improve at Get With The Guidelines-Stroke hospitals
3. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
4. More Evidence That Swings in Blood Pressure Raise Stroke Risk
5. Cellular pathway could provide evidence of how cancer and obesity are linked
6. Palladians Distinguished Clinicians Present at APTAs National CSM Convention in San Diego on Evidenced Informed Management of Chronic Low Back Pain Without Surgery
7. Pew Applauds Federal Grant Program Supporting State Expansion of Evidence-Based Home Visitation
8. Elseviers Journal of Evidence-Based Dental Practice celebrates 10th year with special issue
9. Evidence-based medicine theory can be applied to frequent flying says US professor
10. No Evidence That Lithium Helps in ALS
11. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
Post Your Comments:
Related Image:
More Evidence Cancer Drug Avastin May Cause Harm
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/27/2015)... California (PRWEB) , ... November 27, 2015 , ... Avid ... Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most ... the Canterbury House at the University of Michigan in Ann Arbor. The According to ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology: